We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Hematologic Reference Intervals Defined for Newborns

By LabMedica International staff writers
Posted on 05 Jan 2021
Print article
Image: Hematologic Reference Intervals Defined for Newborns on the XN-1000 Automated Hematology Analyzer (Photo courtesy of Sysmex Corporation).
Image: Hematologic Reference Intervals Defined for Newborns on the XN-1000 Automated Hematology Analyzer (Photo courtesy of Sysmex Corporation).
Laboratory tests leverage 60% to 70% of medical decisions and one of the most often ordered and impactful tests is the complete blood count (CBC). These decisions require that clinicians have a standard for interpreting laboratory test results for their patients.

Ethical constraints exist for performing an unnecessary needle stick and collecting non-clinically indicated blood samples from this vulnerable newborn population. Many newborn CBC Reference Intervals (RI) publications have been retrospective and some authors cite this as one of their cardinal limitations.

A team of medical scientists associated with the Banner – University Medical Center Phoenix, (Phoenix, AZ, USA) conducted a prospective study at an academic tertiary care center, and hematology samples were collected from 120 participants deemed to be normal healthy term newborns. Study enrollment occurred between May 24, 2016, and November 1, 2017. A total of 170 blood specimens were sent to the laboratory.

The team used a single Sysmex XN-1000 Automated Hematology Analyzer (Sysmex America, Lincolnshire, IL, USA) to generate a CBC with white blood cell (WBC) differential for each newborn, including the advanced hematology parameters. Distributions were assessed for normality and tested for outliers. Reference intervals were values between the 2.5th percentile and 97.5th percentile.

The scientists reported that the novel reference intervals obtained for this study population are as follows: absolute immature granulocyte count, 80/μL to 1,700/μL; immature granulocyte percentage, 0.6% to 6.1%; reticulocyte hemoglobin equivalent, 31.7 to 38.4 pg; immature reticulocyte fraction, 35.9% to 52.8%; immature platelet count, 4.73 × 103/μL to 19.72 × 103/μL; and immature platelet fraction, 1.7% to 9.8%.

The authors concluded their prospective study has defined hematologic reference intervals for this newborn population, including new advanced clinical parameters from the Sysmex XN-1000 Automated Hematology Analyzer. These reference intervals are proposed as the new standard and can serve as a strong foundation for continued studies to further explore their value in diagnosing and managing morbidities such as sepsis, anemia, and thrombocytopenia. The study was published in the January, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Banner – University Medical Center Phoenix
Sysmex America


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.